FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083035480> ?p ?o ?g. }

• W2083035480 endingPage "810.e2" @default.
• W2083035480 startingPage "805" @default.
• W2083035480 abstract "Vitamin K antagonists (VKAs) are effective for stroke prevention in patients with atrial fibrillation (AF) but are difficult to use. Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran. It is administered in a fixed dose without laboratory monitoring and is being compared with warfarin (international normalized ratio 2-3) in the RE-LY trial. Two doses of dabigatran (110 and 150 mg BID) are being evaluated. RE-LY is a phase 3, prospective, randomized, open-label multinational (44 countries) trial of patients with nonvalvular AF and at least 1 risk factor for stroke. Recruitment concluded with a total of 18,113 patients. Patients who were VKA-naive and experienced are included in balanced proportions. The primary outcome is stroke (including hemorrhagic) or systemic embolism. Safety outcomes are bleeding, liver function abnormalities, and other adverse events. Adjudication of end points is blinded to drug assignment. The trial is expected to accrue a minimum of 450 events with a minimum 1-year of follow-up. RE-LY is the largest AF stroke prevention trial yet undertaken. It is unique because it includes equal numbers of VKA-experienced and naive patients and evaluates 2 different dosages of dabigatran, which may allow tailoring of dosing to individual patient needs. The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial. Results are expected in 2009." @default.
• W2083035480 created "2016-06-24" @default.
• W2083035480 creator A5003780786 @default.
• W2083035480 creator A5004903930 @default.
• W2083035480 creator A5017248548 @default.
• W2083035480 creator A5018419311 @default.
• W2083035480 creator A5029533765 @default.
• W2083035480 creator A5055275555 @default.
• W2083035480 creator A5069794158 @default.
• W2083035480 creator A5079046512 @default.
• W2083035480 creator A5081398468 @default.
• W2083035480 creator A5081852908 @default.
• W2083035480 date "2009-05-01" @default.
• W2083035480 modified "2023-10-10" @default.
• W2083035480 title "Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran" @default.
• W2083035480 cites W1531871815 @default.
• W2083035480 cites W1586488555 @default.
• W2083035480 cites W1738640266 @default.
• W2083035480 cites W1804375307 @default.
• W2083035480 cites W1967889750 @default.
• W2083035480 cites W1985785080 @default.
• W2083035480 cites W2000438765 @default.
• W2083035480 cites W2019561783 @default.
• W2083035480 cites W2040452288 @default.
• W2083035480 cites W2057484890 @default.
• W2083035480 cites W2106228357 @default.
• W2083035480 cites W2115348966 @default.
• W2083035480 cites W2127211051 @default.
• W2083035480 cites W2133752059 @default.
• W2083035480 cites W2137422676 @default.
• W2083035480 cites W2159193915 @default.
• W2083035480 cites W2403689317 @default.
• W2083035480 cites W2435343268 @default.
• W2083035480 cites W2465663631 @default.
• W2083035480 cites W2499224120 @default.
• W2083035480 cites W4229847571 @default.
• W2083035480 cites W4245449645 @default.
• W2083035480 cites W4362054082 @default.
• W2083035480 doi "https://doi.org/10.1016/j.ahj.2009.02.005" @default.
• W2083035480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19376304" @default.
• W2083035480 hasPublicationYear "2009" @default.
• W2083035480 type Work @default.
• W2083035480 sameAs 2083035480 @default.
• W2083035480 citedByCount "306" @default.
• W2083035480 countsByYear W20830354802012 @default.
• W2083035480 countsByYear W20830354802013 @default.
• W2083035480 countsByYear W20830354802014 @default.
• W2083035480 countsByYear W20830354802015 @default.
• W2083035480 countsByYear W20830354802016 @default.
• W2083035480 countsByYear W20830354802017 @default.
• W2083035480 countsByYear W20830354802018 @default.
• W2083035480 countsByYear W20830354802019 @default.
• W2083035480 countsByYear W20830354802020 @default.
• W2083035480 countsByYear W20830354802021 @default.
• W2083035480 countsByYear W20830354802022 @default.
• W2083035480 countsByYear W20830354802023 @default.
• W2083035480 crossrefType "journal-article" @default.
• W2083035480 hasAuthorship W2083035480A5003780786 @default.
• W2083035480 hasAuthorship W2083035480A5004903930 @default.
• W2083035480 hasAuthorship W2083035480A5017248548 @default.
• W2083035480 hasAuthorship W2083035480A5018419311 @default.
• W2083035480 hasAuthorship W2083035480A5029533765 @default.
• W2083035480 hasAuthorship W2083035480A5055275555 @default.
• W2083035480 hasAuthorship W2083035480A5069794158 @default.
• W2083035480 hasAuthorship W2083035480A5079046512 @default.
• W2083035480 hasAuthorship W2083035480A5081398468 @default.
• W2083035480 hasAuthorship W2083035480A5081852908 @default.
• W2083035480 hasConcept C126322002 @default.
• W2083035480 hasConcept C127413603 @default.
• W2083035480 hasConcept C168563851 @default.
• W2083035480 hasConcept C197934379 @default.
• W2083035480 hasConcept C2776301958 @default.
• W2083035480 hasConcept C2776704044 @default.
• W2083035480 hasConcept C2776710957 @default.
• W2083035480 hasConcept C2777288759 @default.
• W2083035480 hasConcept C2777292125 @default.
• W2083035480 hasConcept C2778810321 @default.
• W2083035480 hasConcept C2779161974 @default.
• W2083035480 hasConcept C2780645631 @default.
• W2083035480 hasConcept C57002609 @default.
• W2083035480 hasConcept C71924100 @default.
• W2083035480 hasConcept C78519656 @default.
• W2083035480 hasConcept C89560881 @default.
• W2083035480 hasConceptScore W2083035480C126322002 @default.
• W2083035480 hasConceptScore W2083035480C127413603 @default.
• W2083035480 hasConceptScore W2083035480C168563851 @default.
• W2083035480 hasConceptScore W2083035480C197934379 @default.
• W2083035480 hasConceptScore W2083035480C2776301958 @default.
• W2083035480 hasConceptScore W2083035480C2776704044 @default.
• W2083035480 hasConceptScore W2083035480C2776710957 @default.
• W2083035480 hasConceptScore W2083035480C2777288759 @default.
• W2083035480 hasConceptScore W2083035480C2777292125 @default.
• W2083035480 hasConceptScore W2083035480C2778810321 @default.
• W2083035480 hasConceptScore W2083035480C2779161974 @default.
• W2083035480 hasConceptScore W2083035480C2780645631 @default.
• W2083035480 hasConceptScore W2083035480C57002609 @default.
• W2083035480 hasConceptScore W2083035480C71924100 @default.
• W2083035480 hasConceptScore W2083035480C78519656 @default.

• next